Eli Lilly and Company (LLY) Up 5.0% — Jump In Now?

  • LLY rose 5.03% to $1302.73 from $1,240.34 the previous trading day
  • Weiss Ratings assigns B (Buy)
  • Market cap is $1.11T with a dividend yield of 0.54%

Eli Lilly and Company (LLY) is pressing into record territory this Tuesday, last trading at $1302.73 on the NYSE. That is a $62.39 gain over the prior close of $1,240.34 and one of the largest single-session moves in dollar terms for any stock in the market. The advance carries LLY roughly 0.78% above its previous 52-week high of $1,292.65, set on August 19, 2026. After two months of consolidating beneath that mark, the stock has broken through decisively, and the market is again pricing Lilly as the leader of the metabolic drug era rather than a crowded trade that has peaked.

Volume stands at approximately 852,676 shares so far, about a third of the 90-day average of roughly 2.62 million, with much of the session still ahead. The stock is clearing a fresh high on that pace.


Why Eli Lilly and Company Price is Moving Higher

The sharpest push came from Wall Street. On October 19, Bank of America kept its Buy rating on Lilly and raised its price target from $1,341 to $1,397, which implies further upside even after today's breakout. The firm based the call on a physician survey showing that Foundayo, Lilly's oral GLP-1, already accounts for 27% of new U.S. oral GLP-1 starts. The same survey projects that share climbing to 40% by 2028–29. That figure matters because the oral GLP-1 market is widely viewed as the next major expansion of the obesity franchise. An early 27% foothold suggests Lilly is establishing the pill as a second growth engine alongside its injectable tirzepatide products, not merely competing for the category.

Regulatory momentum added to the case. On October 15, the European Medicines Agency's expert committee recommended Foundayo for adult weight management and type 2 diabetes, clearing the key scientific hurdle before a final European Commission decision and opening a path to EU revenue. Lilly then reported on October 19 that Omvoh met the primary endpoint of its Phase 3 pediatric ulcerative colitis study, with 50% of responders in remission at one year. That result broadens the immunology drug's addressable population and shows the pipeline extends well beyond obesity. Health Care stocks rose broadly on Tuesday, with Johnson & Johnson (JNJ) up 2.50% and Amgen Inc. (AMGN) up 2.54%. LLY's gain is roughly double those moves, which points to company-specific conviction on top of a supportive sector tape.

The fundamental record gives investors confidence to pay up. Lilly's Q2 report on August 5 showed revenue of $22.97 billion against a $20.69 billion estimate, a 48% year-over-year increase for a company of this size. EPS came in at $8.38 versus the $6.58 consensus, a beat of more than 27%. Management raised full-year 2026 revenue guidance to $85 billion–87 billion from $82 billion–85 billion. With Q3 results scheduled for October 29, today's rally reads as investors positioning ahead of a report that the latest survey and regulatory data suggest could deliver another strong quarter.


What is the Eli Lilly and Company Rating - Should I Buy?

Weiss Ratings assigns LLY a B rating. Current recommendation is Buy. The rating reflects a business firing on nearly every fundamental cylinder, and the stock's performance has confirmed that strength.

Lilly is rated Excellent on the Growth, Efficiency, Solvency, and Total Return indices. The Growth Index rating rests on 47.67% revenue growth, a pace normally seen in small-cap biotechs rather than a $1.11 trillion pharmaceutical giant. The Excellent Efficiency rating is backed by a 33.52% profit margin and a 102.29% return on equity, which shows that heavy spending on manufacturing capacity and late-stage trials has not diluted the earnings power of Mounjaro and Zepbound. The Solvency rating indicates that Lilly can fund its capacity expansion, global launches, and pipeline from its own cash generation. The Excellent Total Return rating is visible in a stock now trading above $1,300 at a new 52-week high.

The picture becomes more nuanced on the Volatility and Dividend indices, both rated Fair. A 5% intraday swing in a trillion-dollar company, driven by a single price-target revision and a regulatory recommendation, shows how sensitive LLY is to each data point on its obesity franchise. A forward P/E of 41.62 means the valuation depends on continued execution, and that explains why the Volatility Index is not rated higher. The Fair Dividend rating reflects a 0.54% yield. Lilly directs its capital toward growth rather than income, which suits investors seeking capital appreciation but offers little cushion for yield-focused holders.

Within the Health Care sector, Eli Lilly is on par with AbbVie Inc. (ABBV, B) and Vertex Pharmaceuticals Incorporated (VRTX, B). It sits ahead of Thermo Fisher Scientific Inc. (TMO, B-) and slightly behind Johnson & Johnson (JNJ, B+) and Amgen Inc. (AMGN, B+), whose steadier trading profiles give them a modest edge in Weiss's risk-adjusted framework. Among those peers, none matches Lilly's combination of revenue growth and return on equity.


About Eli Lilly and Company

Eli Lilly and Company (LLY) is a Health Care company founded in 1876 and headquartered in Indianapolis, Indiana. Lilly discovers, develops, manufactures, and markets medicines across diabetes, obesity, oncology, immunology, and neuroscience. Its commercial portfolio is anchored by tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Together these products have made Lilly the dominant force in incretin-based therapy. The company has extended that position with Foundayo, an oral GLP-1 that gives patients a once-daily pill instead of an injection. Lilly's earlier diabetes products, including Trulicity, Humalog, and Jardiance, which it markets with Boehringer Ingelheim, built the scientific and commercial base for the metabolic franchise.

Lilly's reach extends well beyond metabolic disease. In oncology, Verzenio has become a cornerstone treatment for HR-positive, HER2-negative breast cancer. The immunology portfolio includes Taltz for psoriasis and related inflammatory conditions and Omvoh for ulcerative colitis and Crohn's disease. In neuroscience, Kisunla treats early symptomatic Alzheimer's disease, an area where Lilly has invested for decades.

Lilly's competitive advantages come from first-mover scale in obesity medicine, a late-stage pipeline that keeps replenishing its growth drivers, and a large, ongoing investment in manufacturing capacity to meet demand that has repeatedly outstripped supply. Its sales relationships with endocrinologists and primary care physicians, combined with expanding international regulatory approvals, give it a distribution reach that newer entrants in the GLP-1 space will find difficult to match.


Investor Outlook

Eli Lilly and Company (LLY) carries a Weiss Rating of B (Buy), and today's move to a new 52-week high shows the market rewarding a company whose fundamentals keep running ahead of expectations. The October 29 Q3 report is the next major test. Investors should watch whether revenue keeps pace with the raised $85 billion–87 billion guidance, whether Foundayo's U.S. prescription share continues to build toward the 40% projection, and whether the European Commission finalizes the EMA's recommendation. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.

--

This Weiss Instant News Alert was compiled by narrative data technology, our proprietary ratings models and analysis by Weiss Ratings with the intent of providing our readers with the fastest research and independent coverage. Weiss Instant News Alerts have been reviewed by a member of our editorial staff before publication. Please send any questions or comments about this story to [email protected]
Top Tech Stocks
See All »
B
AAPL NASDAQ $352.45
B
MSFT NASDAQ $508.29
B
NVDA NASDAQ $150.96
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $127.36
B
Top Financial Stocks
See All »
B
A
JPM NYSE $324.11
B
V NYSE $415.22
Top Energy Stocks
See All »
B
CVX NYSE $205.88
B
COP NYSE $134.40
Top Health Care Stocks
See All »
B
LLY NYSE $1,382.75
B
JNJ NYSE $272.70
B
ABBV NYSE $286.01
Top Real Estate Stocks
See All »
B
PLD NYSE $125.22